Dynavax Technologies Corporation (NASDAQ:DVAX) insider Robert Coffman sold 7,500 shares of the business’s stock in a transaction on Wednesday, December 13th. The stock was sold at an average price of $18.90, for a total transaction of $141,750.00. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Shares of Dynavax Technologies Corporation (NASDAQ DVAX) traded up $0.50 during mid-day trading on Friday, reaching $19.25. 3,512,507 shares of the company were exchanged, compared to its average volume of 1,249,331. Dynavax Technologies Corporation has a fifty-two week low of $3.70 and a fifty-two week high of $24.45.

Dynavax Technologies (NASDAQ:DVAX) last announced its earnings results on Friday, November 3rd. The biopharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.53) by $0.15. Dynavax Technologies had a negative net margin of 1,177.60% and a negative return on equity of 65.97%. The business had revenue of $0.05 million for the quarter, compared to analyst estimates of $0.28 million. During the same quarter in the previous year, the firm posted ($0.90) earnings per share. Dynavax Technologies’s revenue was down 68.8% compared to the same quarter last year. analysts expect that Dynavax Technologies Corporation will post -1.72 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently bought and sold shares of DVAX. Vanguard Group Inc. boosted its stake in Dynavax Technologies by 14.4% during the first quarter. Vanguard Group Inc. now owns 1,825,662 shares of the biopharmaceutical company’s stock worth $10,864,000 after buying an additional 230,373 shares in the last quarter. Geode Capital Management LLC boosted its stake in Dynavax Technologies by 6.6% during the first quarter. Geode Capital Management LLC now owns 290,958 shares of the biopharmaceutical company’s stock worth $1,731,000 after buying an additional 18,012 shares in the last quarter. Bank of America Corp DE boosted its stake in Dynavax Technologies by 2.3% during the first quarter. Bank of America Corp DE now owns 20,356 shares of the biopharmaceutical company’s stock worth $121,000 after buying an additional 456 shares in the last quarter. Russell Investments Group Ltd. boosted its stake in Dynavax Technologies by 24.0% during the second quarter. Russell Investments Group Ltd. now owns 155,095 shares of the biopharmaceutical company’s stock worth $1,496,000 after buying an additional 30,036 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. boosted its stake in Dynavax Technologies by 77.6% during the second quarter. Schwab Charles Investment Management Inc. now owns 181,161 shares of the biopharmaceutical company’s stock worth $1,749,000 after buying an additional 79,141 shares in the last quarter. Hedge funds and other institutional investors own 70.61% of the company’s stock.

A number of equities analysts recently issued reports on DVAX shares. Cowen reaffirmed a “buy” rating and set a $30.00 target price on shares of Dynavax Technologies in a research report on Friday, November 3rd. Royal Bank of Canada reaffirmed a “buy” rating and set a $26.00 target price on shares of Dynavax Technologies in a research report on Friday, September 1st. BidaskClub lowered shares of Dynavax Technologies from a “buy” rating to a “hold” rating in a research report on Wednesday, December 6th. ValuEngine raised shares of Dynavax Technologies from a “sell” rating to a “hold” rating in a research report on Thursday, September 7th. Finally, Cantor Fitzgerald started coverage on shares of Dynavax Technologies in a research report on Friday, September 15th. They set an “overweight” rating and a $24.00 target price on the stock. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $25.17.

WARNING: “Dynavax Technologies Corporation (DVAX) Insider Robert Coffman Sells 7,500 Shares” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another website, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be read at https://www.thecerbatgem.com/2017/12/16/dynavax-technologies-corporation-dvax-insider-robert-coffman-sells-7500-shares.html.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Receive News & Stock Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related stocks with our FREE daily email newsletter.